Business
Entrada Therapeutics Reports Third Quarter 2022 Financial Results
On track to submit Investigational New Drug application to the U.S. Food and Drug Administration for ENTR-601-44 for the potential treatment of patients with
About this update from Entrada Therapeutics, Inc.
[{"type":"text","content":"On track to submit Investigational New Drug application to the U.S. Food and Drug Administration for ENTR-601-44 for the potential treatment of patients with Duchenne muscular dystrophy who are exon 44 skipping amenable in the fourth quarter of 2022 Cash runway into 2H 2024 with $216 million in cash, cash equivalents and marketable securities as of September 30, 2022 BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today reported financial results for the third quarter ended September 30, 2022 and highlighted recent business updates. “At Entrada, we are focused on advancing our diverse pipeline of EEV therapeutic candidates, led by our Duchenne muscular dystrophy and myotonic dystrophy type 1 programs. We are well positioned to execute on our strategic initiatives to create value for patients and shareholders alike,” said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics. Entrada expects to file its first Investigational New Drug (IND) application for ENTR-601-44 for patients with Duchenne who are amenable to exon 44 skipping in the fourth quarter of 2022. Following regulatory feedback and potential IND clearance, Entrada plans to initiate a single ascending dose study in healthy volunteers with initial clinical data anticipated in the second half of 2023. A second IND for ENTR-701 for the potential treatment of DM1 is planned for the second half of 2023. The Company is also on track to nominate a clinical candidate for its second Duchenne program, for patients who are amenable to exon 45 skipping, in the fourth quarter of 2022 and has initiated discovery efforts on additional exon skipping programs. There are currently no treatments for patients with Duchenne who are exon 44 skipping amenable or for patients with DM1. Corporate Highlights Presented ENTR-701 preclinical data at the 27th International Annual Congress of the World Muscle Society in Halifax, Canada. ENTR-701 is being developed for the potential treatment of DM1. Following a single dose of EEV-conjugated phosphorodiamidate morpholino oligomer, HSA-LR mice showed normalization of muscle relaxation time 7 days post treatment that was sus...